Roche

News

Roche preps filings for new Ocrevus injection

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

News

ASCO: TIGIT returns with Roche, Gilead data

A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two

News

Foundation aims to level health access with digital tech

A new initiative called the Movement Health Foundation (MHF) has been launched with a pledge to encourage greater use of digital technologies to equalise access to healthc

News

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer

News

Roche’s BTK drug fenebrutinib hits the mark in MS

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv

Roche preps filings for new Ocrevus injection

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

ASCO: TIGIT returns with Roche, Gilead data

Foundation aims to level health access with digital tech

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

Roche’s BTK drug fenebrutinib hits the mark in MS

Telix to buy radiopharma rival ITM for $1.65bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks